Quantcast

Latest Pharmaceutical sciences Stories

2014-09-02 20:23:05

LONDON, Sept. 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Companion Diagnostics: Technologies and Marketshttps://www.reportbuyer.com/product/341176/Companion-Diagnostics-Technologies-and-Markets.html STUDY GOALS AND OBJECTIVESThis BCC Research report, Companion Diagnostics: Technologies and Markets, provides an overview of the current state of development in the companion diagnostics field, existing products on the market and detailed analysis of...

2014-09-02 16:26:02

A "Giveaway to the Drugstore Lobby" is Challenged in Federal Court WASHINGTON, Sept. 2, 2014 /PRNewswire-USNewswire/ -- The Pharmaceutical Care Management Association (PCMA), the national association representing America's pharmacy benefit managers (PBMs), today filed a lawsuit in Iowa federal court challenging a sweeping new Iowa law that restricts tools used by PBMs to lower prescription drug costs for the state's employers and consumers. The law--HF 2297--forces PBMs to overpay for generic...

2014-09-02 16:24:25

AUSTIN, Texas, Sept. 2, 2014 /PRNewswire/ -- On July 31, the Food and Drug Administration sent its 60-day notice to Congress that it is moving forward to regulate laboratory-developed tests (LDTs). The clock is now ticking down the minutes until laboratories throughout the U.S. will need to comply with a host of new requirements. Although some medical laboratories may subscribe to the strategy to simply sit back and wait for the FDA to put guidelines in place, it's widely acknowledged that...

2014-09-02 12:29:19

Neutral displacement line adds to B. Braun's expanding portfolio BETHLEHEM, Pa. and AUSTIN, Texas, Sept. 2, 2014 /PRNewswire/ -- B. Braun Medical Inc. (B.Braun) and RyMed Technologies, LLC announced today that they have entered into a long-term distribution agreement for the InVision-Plus(®) Neutral IV Connector. "The InVision-Plus Neutral IV Connector with Neutral Advantage Technology is designed to inhibit migration of bacteria into the fluid pathway, potentially improving...

2014-09-02 12:29:11

SCHAUMBURG, IL, Sept. 2, 2014 /PRNewswire/ - Catamaran Corp. (NASDAQ: CTRX) (TSX: CCT), a leading provider of technology and pharmacy benefit management (PBM) services, announces that Jeff Park, Executive Vice President of Operations, and Mike Shapiro, Chief Financial Officer, will present at the Morgan Stanley Global Healthcare Conference in New York City. Catamaran's presentation will take place on Tuesday, September 9, 2014, at 2:55 p.m. ET. Catamaran's presentation will be...

2014-09-02 08:31:36

PHILADELPHIA, Sept. 2, 2014 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") today announced that it has developed a recommended approach for protecting personal data in Clinical Study Reports (CSRs) that are shared with researchers, patients and others. The document describes an approach to apply when redacting or removing personal information from CSRs and other related clinical trial documents, and is available here. The goal of the TransCelerate CSR Redaction...

2014-09-02 08:31:24

Company Controls Significant, Industry First Patent; Covers System for Identity Verification, Monitoring, and Development of Medicine in Marijuana Businesses LOS ANGELES, Sept. 2, 2014 /PRNewswire/ --?Medbox, Inc. (OTCQB: MDBX) (www.medbox.com), a leading dispensary infrastructure/licensing specialist, patented technology provider, and partner to the cannabis industry, today announced that the US Patent and Trademark Office (USPTO) has issued patent #US8818820 and assigned it to Medbox, Inc....

2014-09-02 08:30:36

Data from Multi-Center, Placebo-Controlled Study Anticipated in Q1 2015 SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed enrollment in a randomized Phase II clinical trial of its lead investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk...

2014-09-02 08:29:58

SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman and Renshaw 16(th) Annual Global Investment Conference on Tuesday, September 9, 2014 at 2:55 p.m. Eastern time in the Holmes II Salon at The New York Palace Hotel in New York. Interested parties can access a live audio webcast and slide presentation on the Mast Therapeutics web site at...

2014-09-02 08:29:52

SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension. "The FDA Office of Orphan Products Development (OOPD) evaluates scientific and clinical data submissions from sponsors to identify and designate drug candidates that could potentially treat rare diseases to help advance the evaluation and...


Latest Pharmaceutical sciences Reference Libraries

Phytotherapy Research
2012-05-01 10:17:25

Phytotherapy Research is a monthly peer-reviewed scientific journal publishing original research papers, short communications, reviews, and letters on medicinal plant research. Topics include pharmacology, toxicology, and the clinical applications of herbs and natural products in medicine, from case histories to clinical trials, including studies of herb-drug interactions and other aspects of the safety of herbal medicines. Short communications dealing with the pharmacology and screening...

More Articles (1 articles) »
Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related